Closed Surgical Wound Drainage Market Forecast till 2030

Description

List of Tables

Cardinal Health (US), Zimmer Biomet (US), Axiom Medical, Inc. (US), Angiplast Pvt. Ltd. (India), Polymedicure (India), Becton, Dickinson, and Company (US), Braun SE (Germany), StayGuard (US), Medline Industries, Inc. (US), and VariVac International Medical Research Pty Ltd. (Australia), Ingelheim (Ingelheim am Rhein, Germany), Vetoquinol (Lure, France), Ceva Animal Health, LLC (Libourne, France), Chanelle Pharma (Galway, Ireland), Elanco (Indiana, US), SOMAVAC Medical Solutions, Inc. (US).

Product Code: MRFR/HC/17293-HCR

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCE OF CHRONIC WOUNDS AND SURGICAL SITE INFECTIONS
- 4.2.2 RISING PREVALENCE OF CHRONIC DISEASES
- 4.2.3 RISING AWARENESS ABOUT THE BENEFITS OF CLOSED SURGICAL WOUND DRAINAGE AND TECHNOLOGICAL ADVANCEMENTS
4.3 RESTRAINTS
- 4.3.1 INCREASING CONCERNS OVER SIDE EFFECTS
- 4.3.2 RISE IN THE NUMBER OF MINIMALLY INVASIVE SURGERIES
4.4 OPPORTUNITIES
- 4.4.1 GROWING AGING POPULATION

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET
- 5.3.1 IMPACT ON MARKET GROWTH
- 5.3.2 DEMAND SUPPLY ANALYSIS
- 5.3.3 IMPACT ON KEY PLAYERS
5.4 REIMBURSEMENT SCENARIO FOR CLOSED SURGICAL WOUND DRAINAGE
- 5.4.1 REIMBURSEMENT SCENARIO BY COUNTRY

6 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 CLOSED SURGICAL DRAINAGE SYSTEMS
6.3 ACCESSORIES

7 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY TYPE

7.1 OVERVIEW
7.2 ACTIVE DRAINS
7.3 PASSIVE DRAINS

8 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY AGE GROUP

8.1 OVERVIEW
8.2 ADULT
8.3 PAEDIATRIC

9 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY APPLICATION

9.1 OVERVIEW
9.2 GENERAL SURGERY
9.3 ORTHOPEDICS SURGERY
9.4 CARDIAC & THORACIC SURGERY
9.5 OBSTETRIC/GYNECOLOGICAL SURGERY
9.6 OTHERS

10 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY END USER

10.1 OVERVIEW
10.2 HOSPITALS & CLINICS
10.3 AMBULATORY SURGICAL CENTERS
10.4 OTHERS

11 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY REGION

11.1 OVERVIEW
11.2 NORTH AMERICA
- 11.2.1 US
- 11.2.2 CANADA
11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.2 FRANCE
- 11.3.3 UK
- 11.3.4 ITALY
- 11.3.5 SPAIN
- 11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
- 11.4.1 CHINA
- 11.4.2 INDIA
- 11.4.3 JAPAN
- 11.4.4 SOUTH KOREA
- 11.4.5 AUSTRALIA
- 11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
- 11.5.1 AFRICA
- 11.5.2 LATIN AMERICA
- 11.5.3 MIDDLE EAST

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET
12.5 FINANCIAL MATRIX
- 12.5.1 SALES (USD MILLION), 2022
- 12.5.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022

13 COMPANY PROFILES

13.1 CARDINAL HEALTH
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 PRODUCTS OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
13.2 ZIMMER BIOMET
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 PRODUCTS OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 SWOT ANALYSIS
- 13.2.6 KEY STRATEGIES
13.3 AXIOM MEDICAL, INC
- 13.3.1 COMPANY OVERVIEWS
- 13.3.2 FINANCIAL OVERVIEW
- 13.3.3 PRODUCTS OFFERED
- 13.3.4 KEY DEVELOPMENTS
- 13.3.5 KEY STRATEGIES
13.4 ANGIPLAST PVT. LTD
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 PRODUCTS OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 KEY STRATEGIES
13.5 POLYMEDICURE
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 PRODUCTS OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 KEY STRATEGIES
13.6 BECTON, DICKINSON AND COMPANY
- 13.6.1 COMPANY OVERVIEW
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 PRODUCTS OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 SWOT ANALYSIS
- 13.6.6 KEY STRATEGIES
13.7 B. BRAUN SE
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 PRODUCTS OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 SWOT ANALYSIS
- 13.7.6 KEY STRATEGIES
13.8 STAYGUARD
- 13.8.1 COMPANY OVERVIEW
- 13.8.2 PRODUCTS OFFERED
- 13.8.3 KEY DEVELOPMENTS
- 13.8.4 KEY STRATEGIES
13.9 MEDLINE INDUSTRIES, INC
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 PRODUCTS OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 SWOT ANALYSIS
- 13.9.6 KEY STRATEGIES
13.10 VARIVAC INTERNATIONAL MEDICAL RESEARCH PTY LTD
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL OVERVIEW
- 13.10.3 PRODUCTS OFFERED
- 13.10.4 KEY DEVELOPMENTS
- 13.10.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES
14.2 RELATED REPORTS